Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Yükleniyor...
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
BioMed Central Ltd
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which
subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to
show the efectiveness of systemic treatments after CDKi and whether there is a survival diference between hormonal treatments (monotherapy vs. mTOR-based).
Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients
were evaluated in three groups as those who received CDKi in frst-line (group A, n:202), second-line (group B, n: 153)
and≥3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared
as monotherapy versus everolimus-based combination therapy.
Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of
group A, and 5.3 (3.9–6.8) months in the CT arm (p=0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and
5.7 (4.6–6.7) months in the CT arm (p=0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6)
months in the CT arm (p=0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C
was 11.0 vs. 5.9 (p=0.047), 6.7 vs. 5.0 (p=0.164), 6.7 vs. 3.9 (p=0.763) months.
Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown
that subsequent ET after CDKi can be as efective as CT. It was also observed that better PFS could be achieved with
the subsequent everolimus-based treatments after frst-line CDKi compared to monotherapy ET.
Açıklama
Anahtar Kelimeler
Advanced breast cancer, Cyclin-dependent kinase, Ribociclib, Palbociclib, Everolimus, Fulvestrant, Endocrine treatment, Hormonotherapy
Kaynak
BMC Cancer
WoS Q Değeri
N/A
Scopus Q Değeri
Q2
Cilt
23
Sayı
1
Künye
Karaçin, C., Öksüzoğlu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F. ve diğerleri. (2023). Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer, 23(1), 1-10.
